Skip Navigation



Annals of Oncology Advance Access published online on August 8, 2005
Annals of Oncology, doi:10.1093/annonc/mdi365
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/11/1811    most recent
mdi365v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dy, G. K.
Right arrow Articles by Adjei, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dy, G. K.
Right arrow Articles by Adjei, A. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received May 18, 2005
Revised June 17, 2005
Accepted June 21, 2005

Original article

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study

G. K. Dy 1, A. A. Miller 2, S. J. Mandrekar 1, M.-C. Aubry 1, R. M. Langdon Jr.3, R. F. Morton 4, S. E. Schild 5, J. R. Jett 1, and A. A. Adjei 1*

1 Mayo Clinic and Mayo Foundation, Rochester, MN 55905
2 Wake Forest University School of Medicine, Winston-Salem, NC 27157
3 Missouri Valley Cancer Consortium, Omaha, NE 68106
4 Iowa Oncology Research Association CCOP, Des Moines, IA 50309-1014
5 Scottsdale CCOP, Scottsdale, AZ 85259-5404, USA

* To whom correspondence should be addressed.
A. A. Adjei, E-mail: adjei.alex{at}mayo.edu


  Abstract

Background: The aim of the present study was to evaluate the clinical activity of imatinib mesylate in patients with recurrent and refractory c-kit-expressing small-cell lung cancer.

Patients and methods: Patients with c-kit-expressing SCLC (≥1+ by immunohistochemistry) were enrolled in two groups. Arm A included patients with disease progression <3 months and arm B included patients with disease progression ≥3 months after previous treatment. Imatinib was administered at a dose of 400 mg b.i.d. continuously, with a cycle length of 28 days. A single stage Simon design with a planned interim analysis was used to evaluate the 16-week progression free rate in each arm.

Results: A total of 29 evaluable patients were entered into the study (seven in arm A, median age 68; 22 in arm B, median age 64.5). Median number of treatment cycles was one in both arms. Grade 3+ non-hematologic adverse events were seen in 15 (52%) patients, with nausea, vomiting, dyspnea, fatigue, anorexia and dehydration each occurring in at least 10% of patients. Median survival was 3.9 and 5.3 months and median time to progression was 1 and 1.1 months for arms A and B, respectively. Enrollment to arm A was temporarily suspended prior to reaching interim analysis due to striking early disease progression (29%), early deaths (29%) and patient refusal (42%). No objective responses and no confirmed stable disease ≥6 weeks were seen in either arm. Accrual was permanently terminated to both arms as only one patient was progression-free at 16 weeks.

Conclusion: Imatinib failed to demonstrate any clinical activity in spite of patient selection for c-kit-expressing SCLC. Our results strengthen the collective evidence that prediction of efficacy of novel therapeutic agents based on target expression, rather than pathway activation (for example, through activating mutations), may not be a valid paradigm for drug development.

Keywords: c-kit; imatinib; kinase inhibitors; small-cell lung cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. L. Hurwitz, F. McCoy, P. Scullin, and D. A. Fennell
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
Oncologist, October 1, 2009; 14(10): 986 - 994.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
L. M. Krug and M. C. Pietanza
Emerging Therapies in Small Cell Lung Cancer
ASCO Educational Book, January 1, 2009; 2009(1): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. H. El-Maraghi and E. A. Eisenhauer
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
J. Clin. Oncol., March 10, 2008; 26(8): 1346 - 1354.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
T. Sher, G. K. Dy, and A. A. Adjei
Small Cell Lung Cancer
Mayo Clin. Proc., March 1, 2008; 83(3): 355 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke
Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
T. Gudermann and S. Roelle
Calcium-dependent growth regulation of small cell lung cancer cells by neuropeptides
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1069 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. Rehfeld, H. Geddert, A. Atamna, H. E. Gabbert, U. Steidl, R. Fenk, R. Kronenwett, R. Haas, and U.-P. Rohr
Coexpression of Fragile Histidine Triad and c-kit Is Relevant for Prediction of Survival in Patients with Small Cell Lung Cancer.
Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2232 - 2238.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Brade and I. F. Tannock
Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure?
J. Clin. Oncol., March 1, 2006; 24(7): 1020 - 1022.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.